P/E ratio for I-Mab Biopharma (IMAB)
P/E ratio as of May 2024 (TTM): 1.28
According to I-Mab Biopharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 1.2817. At the end of 2021 the company had a P/E ratio of -9.94.
P/E ratio history for I-Mab Biopharma from 2020 to 2020
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -9.94 | -129% |
| 2020 | 34.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.81 | -475.66% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -177.65% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.